Phase 1 Study to Evaluate Safety, Dosage, and Effectiveness of PLT012 in Adults with Advanced Solid Tumor Cancers

What this Trial Is About

Researchers are conducting a phase 1 study to evaluate the safety, tolerability, and initial effectiveness of PLT012, an anti-CD36 monoclonal antibody, in adults with advanced solid tumors. The study aims to find safe dose levels of PLT012, understand side effects, measure how the drug behaves in the body, and observe its impact on tumor size and cancer progression. Participants will receive PLT012 through an intravenous infusion every three weeks. Treatment may continue until the cancer worsens or side effects prevent further use. During the first 12 weeks, clinic visits may occur 1 to 5 times within each 3-week period for close monitoring, then reduce to once every 3 weeks thereafter. Throughout the study, participants will undergo evaluations including safety assessments, blood tests for drug levels, and tumor measurements. Researchers will monitor side effects, treatment response, and immune reactions over an 18-month period. This trial is sponsored by Pilatus Biosciences Inc and focuses on adults aged 18 and older with measurable advanced solid tumors.

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers